SNGX

0.22018.29%
GA

Gregory Anthony Lapointe

Independent Chairman of the Board

Mr. Gregory Anthony Lapointe, CPA, MBA, also known as Gregg, serves as an Independent Director at Soligenix, Inc. since March 10, 2009. He serves as Co-Founder, Chief Executive Officer & Director at Cerium Pharmaceuticals, Inc. He serves as Director at Tarix Pharmaceuticals LTD. He was an Independent Director at Astria Therapeutics, Inc. since January 4, 2019 until January 23, 2026. Mr. Lapointe is a Co-Founder of Cerium Pharmaceuticals, Inc. and has been its Chief Executive Officer since April 2012. Mr. Lapointe has broad experience in the pharmaceutical and medical device industries. He served as the Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. from April 2008 to February 2012. He served as Chief Executive Officer of Sigma-Tau Pharmaceuticals at Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. He served as the Chief Operating Officer of Sigma Tau Pharmasource, Inc. until 2012. He served as the Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc. from November 2003 to April 2008. He served as Chief Financial Officer of Sigma-Tau Pharmaceuticals, Inc. form 2001 to 2002. He joined Sigma-Tau in September 2001 and served as its Vice President of Finance and Vice President of Operations since August 2002. He served as Vice President of Operations, Vice President and Controller for AstenJohnson, Inc. from May 1996 to August, 2001. Mr. Lapointe held various financial and operations roles at Medical Plastic Devices, Inc. and Ingram & Bell Meditron. Prior to joining Ingram & Bell Meditron, he served as a Senior Manager at Zittrer Siblin Stein Levine, a management consultant mergers and acquisitions firm based in Montreal, Canada. Mr. Lapointe served for years in the Canadian medical products industry in a variety of roles, including Vice President and General Manager of a large medical products distributor and Chief Financial Officer of a medical products manufacturer. He began his career with PriceWaterhouseCoopers in 1982 as a Chartered Accountant with progressive advancement from Staff Accountant to Audit Manager. His background includes extensive experience in the areas of Global Strategic Planning and Implementation, Business Development, Corporate Finance and Acquisitions. He served as the Chairman of the Board at Raptor Pharmaceuticals Corp. from August 2015 to October 25, 2016. Mr. Lapointe has been a Director of DOR BioPharma, Inc. since March 10, 2009, S1 Biopharma Inc. since August 2014. He is Independent Director at Rigel Pharmaceuticals, Inc. since November 2017 and serves as its Independent Chairman of the Board. Mr. Lapointe offers Rigel’s board commercial and financial experience bringing products to market in the areas of medical devices and rare diseases. He had been an Independent Director of Cytori Therapeutics (Plus Therapeutics, Inc.), Inc. since March 31, 2017 until January 31, 2020. He serves as a Director of EP Global Communications, Inc. He serves on the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. Mr. Lapointe served as a Director of Cambrooke Therapeutics, Inc. He served as a Director of Pharmaceuticals Research and Manufacturers of America (PhRMA) from 2009 to 2012. He served as a Director of Raptor Pharmaceuticals Corp. from December 2014 to October 25, 2016. He served as an Independent Director of ImmunoCellular Therapeutics, Ltd. from September 22, 2015 to August 15, 2017. He served as a Director of SciClone Pharmaceuticals, Inc. from March 2009 to October 13, 2017. He served as a Director of Questcor Pharmaceuticals, Inc. since October 12, 2009 and served as its Director from July 6, 2005 to August 30, 2007. He serves as a Member of the Corporate Council of the National Organization for Rare Diseases (NORD), the Child Neurology Foundation and Kidney Care Partners. He is a Certified Public Accountant in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe holds a B.A. degree in Commerce from Concordia University (Montreal, Canada), a Graduate Diploma in Accountancy from McGill University (Montreal, Canada) and a Master's Degree in Business Administration from the Fuqua School of Business, Duke University.

Positions